Before I joined to C4U, I worked for one of the Japanese mid-seize pharmaceutical companies, Kissei Pharmaceutical Co., Ltd. for 34yrs. At the company, I got experiences every step from discovery, pharmacology and clinical development, product planning, and BD for one drug. I joined to C4U from September in 2021 as a director of BD. Our platform, CRISPR-Cas3 has a great potential. It is truly my motivation. I would like to use our CRISPR-Cas3 for the benefit of society.